Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Wu, Yanyuan ^a,b   Alvarez, Monica ^a   Slamon, Dennis J ^b   Koeffler, Phillip ^b,c   Vadgama, Jaydutt V ^a,b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE 8; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; FLUOROURACIL; HISTONE H3; MASPIN; TRICHOSTATIN A; HYDROXAMIC ACID; SERINE PROTEINASE INHIBITOR; SERPIN B5; SERPIN-B5;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; BIOLOGICAL MODEL; BIOSYNTHESIS; BREAST TUMOR; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CASPASE 8; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; MODELS, BIOLOGICAL; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERPINS;

EID: 77349089525     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-32     Document Type: Article

References (53)

1. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP. S-Adenosylmethionine and methylation. FASEB J 1996, 10:471-480.
2. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998, 72:141-196. full_text, 9338076.
3. Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocr Relat Cancer 2001, 8:115-127. 10.1677/erc.0.0080115, 11446343.
4. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002, 21:5462-5482. 10.1038/sj.onc.1205606, 12154408.
5. Miyakura Y, Sugano K, Konishi F, Ichikawa A, Maekawa M, Shitoh K, Shitoh K, Igarashi S, Kotake K, Koyama Y, Nagai H. Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology 2001, 121:1300-1309. 10.1053/gast.2001.29616, 11729109.
6. Ricciardiello L, Goel A, Mantovani V, Fiorini T, Fossi S, Chang DK, Lunedei V, Pozzato P, Zagari RM, De Luca L, Fuccio L, Martinelli GN, Roda E, Boland CR, Bazzoli F. Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. Cancer Res 2003, 63:787-792.
7. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008, 8:17. 10.1186/1471-2407-8-17, 2245962, 18208621.
8. Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, Grushko TA, Olopade OI. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat 2008, 111:113-120. 10.1007/s10549-007-9766-6, 17932744.
9. Fiegl H, Millinger S, Goebel G, Müller-Holzner E, Marth C, Laird PW, Widschwendter M. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 2006, 66:29-33. 10.1158/0008-5472.CAN-05-2508, 16397211.
10. Salvesen GS. Caspase-8: igniting the death machine. Structure 1999, 7:R225-229. 10.1016/S0969-2126(00)80048-9, 10545333.
11. Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Phillips PC, Shalaby T, Grotzer MA. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 2003, 9:6401-6409.
12. Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, London WB, Cohn SL. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007, 13:3191-3197. 10.1158/1078-0432.CCR-06-2846, 17545522.
13. Khalkhali-Ellis Z. Maspin: the new frontier. Clin Cancer Res 2006, 12:7279-7283. 10.1158/1078-0432.CCR-06-1589, 17189399.
14. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18:1427-1431. 10.1093/bioinformatics/18.11.1427, 12424112.
15. Kuo M-H, Allis CD. In vivo cross-linking and immunoprecipitation for studying dynamic protein:DNA associations in a chromatin environment. Methods 1999, 19:425-433. 10.1006/meth.1999.0879, 10579938.
16. Trojer P, Reinberg D. Histone lysine demethylases and their impact on epigenetics. Cell 2006, 125:213-217. 10.1016/j.cell.2006.04.003, 16630806.
17. Lan F, Bayliss PE, Rinn JL, Whetstine JR, Wang JK, Chen S, Iwase S, Alpatov R, Issaeva I, Canaani E, Roberts TM, Chang HY, Shi Y. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature 2007, 449:689-694. 10.1038/nature06192, 17851529.
18. Zoli W, Ulivi P, Tesei A, Fabbri F, Rosetti M, Maltoni R, Giunchi DC, Ricotti L, Brigliadori G, Vannini I, Amadori D. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res 2005, 7:R681-689. 10.1186/bcr1274, 1242133, 16168113.
19. Ehrhardt H, Häcker S, Wittmann S, Maurer M, Borkhardt B, Toloczko A, Debatin KM, Fulda S, Jeremias I. Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene 2008, 27:783-793. 10.1038/sj.onc.1210666, 17637740.
20. Barton CA, Hacker NF, Clark SJ, O'Brien PM. DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008, 109:129-139. 10.1016/j.ygyno.2007.12.017, 18234305.
21. Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 2007, 177:822-831. 10.1016/j.juro.2006.10.063, 17296351.
22. Yuan J, Luo RZ, Fuji S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 2003, 63:4174-4180.
23. Chen K, Sawhney R, Khan M, Benninger MS, Hou Z, Sethi S, Stephen JK, Worsham MJ. Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2007, 133:1131-1138. 10.1001/archotol.133.11.1131, 18025318.
24. Ellinger J, El Kassem N, Heukamp LC, Matthews S, Cubukluoz F, Kahl P, Perabo FG, Müller SC, von Ruecker A, Bastian PJ. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol 2008, 179:346-352. 10.1016/j.juro.2007.08.091, 18006010.
25. Park do Y, Sakamoto H, Kirley SD, Ogino S, Kawasaki T, Kwon E, Mino-Kenudson M, Lauwers GY, Chung DC, Rueda BR, Zukerberg LR. The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer. Am J Pathol 2007, 171:1509-1519. 10.2353/ajpath.2007.070331, 2043512, 17982127.
26. Henken FE, Wilting SM, Overmeer RM, Rietschoten JG, Nygren AO, Errami A, Schouten JP, Meijer CJ, Snijders PJ, Steenbergen RD. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer 2007, 97:1457-1464. 10.1038/sj.bjc.6604055, 2360246, 17971771.
27. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S. High frequency of hypermethylation at the 14-3-3 s locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000, 97:6049-6054. 10.1073/pnas.100566997, 18556, 10811911.
28. Graff JR, Herman JG, Lapidus RL, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995, 55:5195-5199.
29. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999, 59:798-802.
30. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103-107. 10.1038/5047, 9916800.
31. Martinez R_, Setien F, Voelter C, Casado S, Quesada MP, Schackert G, Esteller M. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 2007, 28:1264-1268. 10.1093/carcin/bgm014, 17272309.
32. Eramo A, Pallini R, Lotti F, Sette G, Patti M, Bartucci M, Ricci-Vitiani L, Signore M, Stassi G, Larocca LM, Crinò L, Peschle C, De Maria R. Inhibition of DNA Methylation Sensitizes Glioblastoma for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Destruction. Cancer Research 2005, 65:11469-11477. 10.1158/0008-5472.CAN-05-1724, 16357155.
33. Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Matta H, Miyajima K, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Chaudhary PM, Gazdar AF. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 2002, 62:5897-5901.
34. Liedtke C, Groger N, Manns MP, Trautwein C. The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be upregulated by a p53-dependent mechanism. J Biol Chem 2003, 278:27593-27604. 10.1074/jbc.M304077200, 12748179.
35. Chaudhary PM, Eby MT, Jasmin A, Kumar A, Liu L, Hood L. Activation of the NF-kappaB pathway by caspase-8 and its homologs. Oncogene 2000, 19:4451-4460. 10.1038/sj.onc.1203812, 11002417.
36. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ. Caspase-8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000, 6:529-535. 10.1038/75007, 10802708.
37. Fulda S, Debatin KM. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 2002, 21:2295-2308. 10.1038/sj.onc.1205255, 11948413.
38. Magdinier F, Wolffe AP. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA 2001, 98:4990-4995. 10.1073/pnas.101617298, 33151, 11309512.
39. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389. 10.1038/30764, 9620804.
40. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998, 19:187-191. 10.1038/561, 9620779.
41. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Genet 2002, 3:415-428.
42. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103-107. 10.1038/5047, 9916800.
43. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-a by DNA methyltransferase and histone deacetylase inhibition in human ER-a negative breast cancer cells. Cancer Res 2001, 61:7025-7029.
44. Qi W, Wu H, Yang L, Boyd DD, Wang Z. A novel function of caspase-8 in the regulation of androgen-receptor-driven gene expression. EMBO 2007, 26:65-75.
45. Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ. Biological functions of maspin. J Cell Physiol 2006, 209:617-624. 10.1002/jcp.20782, 17001697.
46. Zhang W, Shi HY, Zhang M. Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer 2005, 5(50).
47. Sheng S. The promise and challenge toward the clinical application of maspin in cancer. Front Biosci 2004, 9:2733-2745. 10.2741/1432, 15353310.
48. Odero-Marah VA, Khalkhali-Ellis Z, Chunthapong J, Amir S, Seftor RE, Seftor EA, Hendrix MJ. Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther 2003, 2:398-403.
49. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000, 6:196-199. 10.1038/72303, 10655109.
50. Domann FE, Rice JC, Hendrix MJ, Futscher BW. Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 2000, 85:805-810. 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5, 10709100.
51. Rinkenberger JL, Korsmeyer SJ. Errors of homeostasis and deregulated apoptosis. Curr Opin Genet Dev 1997, 7:589-596. 10.1016/S0959-437X(97)80004-4, 9388773.
52. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999, 11:58-75. 10.1097/00001622-199901000-00014, 9914880.
53. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000, 21:485-495. 10.1093/carcin/21.3.485, 10688869.